New interferon beta-like molecules

The invention relates to a conjugate exhibiting interferon ² activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon ² polypeptide, the amino acid sequence of which differs from that of wildtype human interferon ² in at least one introduced and at least...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: RASMUSSEN, POUL BAAD, PEDERSEN, ANDERS, HJELHOLT, RASMUSSEN, GRETHE, DRUSTRUP, JORN
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator RASMUSSEN, POUL BAAD
PEDERSEN, ANDERS, HJELHOLT
RASMUSSEN, GRETHE
DRUSTRUP, JORN
description The invention relates to a conjugate exhibiting interferon ² activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon ² polypeptide, the amino acid sequence of which differs from that of wildtype human interferon ² in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent interferon ² (IFNB) polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2080771A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2080771A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2080771A33</originalsourceid><addsrcrecordid>eNrjZFDySy1XyMwrSS1KSy3Kz1NISi1J1M3JzE5VyM3PSU0uzUkt5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BRgYWBubmho7GxkQoAQBniCWk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>New interferon beta-like molecules</title><source>esp@cenet</source><creator>RASMUSSEN, POUL BAAD ; PEDERSEN, ANDERS, HJELHOLT ; RASMUSSEN, GRETHE ; DRUSTRUP, JORN</creator><creatorcontrib>RASMUSSEN, POUL BAAD ; PEDERSEN, ANDERS, HJELHOLT ; RASMUSSEN, GRETHE ; DRUSTRUP, JORN</creatorcontrib><description>The invention relates to a conjugate exhibiting interferon ² activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon ² polypeptide, the amino acid sequence of which differs from that of wildtype human interferon ² in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent interferon ² (IFNB) polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20100106&amp;DB=EPODOC&amp;CC=EP&amp;NR=2080771A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20100106&amp;DB=EPODOC&amp;CC=EP&amp;NR=2080771A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RASMUSSEN, POUL BAAD</creatorcontrib><creatorcontrib>PEDERSEN, ANDERS, HJELHOLT</creatorcontrib><creatorcontrib>RASMUSSEN, GRETHE</creatorcontrib><creatorcontrib>DRUSTRUP, JORN</creatorcontrib><title>New interferon beta-like molecules</title><description>The invention relates to a conjugate exhibiting interferon ² activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon ² polypeptide, the amino acid sequence of which differs from that of wildtype human interferon ² in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent interferon ² (IFNB) polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFDySy1XyMwrSS1KSy3Kz1NISi1J1M3JzE5VyM3PSU0uzUkt5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BRgYWBubmho7GxkQoAQBniCWk</recordid><startdate>20100106</startdate><enddate>20100106</enddate><creator>RASMUSSEN, POUL BAAD</creator><creator>PEDERSEN, ANDERS, HJELHOLT</creator><creator>RASMUSSEN, GRETHE</creator><creator>DRUSTRUP, JORN</creator><scope>EVB</scope></search><sort><creationdate>20100106</creationdate><title>New interferon beta-like molecules</title><author>RASMUSSEN, POUL BAAD ; PEDERSEN, ANDERS, HJELHOLT ; RASMUSSEN, GRETHE ; DRUSTRUP, JORN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2080771A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2010</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>RASMUSSEN, POUL BAAD</creatorcontrib><creatorcontrib>PEDERSEN, ANDERS, HJELHOLT</creatorcontrib><creatorcontrib>RASMUSSEN, GRETHE</creatorcontrib><creatorcontrib>DRUSTRUP, JORN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RASMUSSEN, POUL BAAD</au><au>PEDERSEN, ANDERS, HJELHOLT</au><au>RASMUSSEN, GRETHE</au><au>DRUSTRUP, JORN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>New interferon beta-like molecules</title><date>2010-01-06</date><risdate>2010</risdate><abstract>The invention relates to a conjugate exhibiting interferon ² activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon ² polypeptide, the amino acid sequence of which differs from that of wildtype human interferon ² in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent interferon ² (IFNB) polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP2080771A3
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
title New interferon beta-like molecules
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A46%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=RASMUSSEN,%20POUL%20BAAD&rft.date=2010-01-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2080771A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true